search
Back to results

Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

Primary Purpose

Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)

Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Bupropion
Sponsored by
Indiana University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Male and female (approximately 1:1) volunteers between the age of 18 and 55 years old and within 32% of your ideal body weight.
  • Judged healthy without any significant medical condition as determined by and decided from a pre-enrollment screening session that include medical history, laboratory tests such as blood and urine tests, and an electrical tracing of the heart beat (electrocardiogram, EKG).
  • Individuals who agree to refrain from taking any prescriptions medications, over-the-counter medications, and herbal, dietary, and alternative supplements that may interact with the metabolism of those study drugs at least 2 weeks prior to the start of the study and until study completion.
  • Nonsmoker or individuals willing to refrain from smoking or use of tobacco or marijuana for at least two weeks prior to and until the completion of the study (the entire study lasts for approximately 32 days).
  • Willing to commit the time requested for this study

Exclusion Criteria:

Subjects will be excluded from the study if they:

  • Are underweight (weigh less than 52 kg or 114 lb) or overweight [body mass index (BMI) greater than 32].
  • Have laboratory results that do not fall in a healthy range (e.g., blood hemoglobin less than 12.0 mg/dl).
  • Have baseline EKG readings that are abnormal that could place the patient at the higher risk as decided by the study medical doctor (MD)
  • Have history of intolerance, allergic reactions (e.g. rash) or other forms of hypersensitivities to any of the study medications (dextromethorphan and bupropion).
  • Have current alcohol (more than 4 alcoholic drinks per day on a regular basis) or drug abuse.
  • Have history or current gastrointestinal (digestive) disorders such as persistent diarrhea or malabsorption that would interfere with the absorption of orally administered drugs
  • Have history or current seizures, hypertension and heart disease or any other cardiovascular disorders
  • Have history or current psychiatric (mental or brain) disorders (e.g., feeling sad or unhappy, loss of interest in normal activities, worried) such as depression, anxiety, or suicidality or suicide attempts.
  • Have significantly compromised liver and/or kidney functions.
  • Have participated in a research study involving intensive blood sampling or have donated blood within the past two months
  • Are unable or unwilling to stop taking other substances that may interfere with the metabolism of the study drugs (bupropion and dextromethorphan) two weeks prior to and during the entire study period, including prescription medications, over-the-counter medications, herbal or dietary supplements, and alternative medicines.
  • Are employees or students under supervision of any of the study investigators.
  • Cannot state a good understanding of this study including risks and requirements; are unable to follow the rules of this study.
  • Cannot commit the time requested for this study.

Sites / Locations

  • Indiana Clinical Research Center (ICRC)

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Baseline CYP2D6 activity

CYP2D6 activity with single dose of bupropion

CYP2D6 activity after treatment with bupropion to steady sate

Arm Description

CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).

The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.

CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).

Outcomes

Primary Outcome Measures

Exposure
Area under the plasma concentration versus time curves (AUC0-inf) of bupropion and its metabolites as well as CYP2D6 activity measured by dextromethorphan to dextrorphan

Secondary Outcome Measures

Full Information

First Posted
January 26, 2018
Last Updated
December 19, 2019
Sponsor
Indiana University
Collaborators
National Institute of General Medical Sciences (NIGMS)
search

1. Study Identification

Unique Protocol Identification Number
NCT03420469
Brief Title
Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
Official Title
Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
June 5, 2018 (Actual)
Primary Completion Date
May 1, 2019 (Actual)
Study Completion Date
May 1, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana University
Collaborators
National Institute of General Medical Sciences (NIGMS)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Primary objectives: To comprehensively characterize steady state stereoselective pharmacokinetics of bupropion and its primary and secondary metabolites in healthy volunteers To prospectively determine the time course (onset), extent and offset of CYP2D6 inhibition in relation to the pharmacokinetic profiles of bupropion and metabolites.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Sequential Assignment
Model Description
This is an open-label, four-phases, fixed sequence healthy volunteers study investigating: the steady state stereoselective disposition of bupropion and metabolites; and effect of multiple doses of bupropion on CYP2D6 activity, as measured by the metabolism and pharmacokinetics of a single dose of dextromethorphan
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
28 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Baseline CYP2D6 activity
Arm Type
Experimental
Arm Description
CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).
Arm Title
CYP2D6 activity with single dose of bupropion
Arm Type
Experimental
Arm Description
The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.
Arm Title
CYP2D6 activity after treatment with bupropion to steady sate
Arm Type
Experimental
Arm Description
CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).
Intervention Type
Drug
Intervention Name(s)
Bupropion
Intervention Description
Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
Primary Outcome Measure Information:
Title
Exposure
Description
Area under the plasma concentration versus time curves (AUC0-inf) of bupropion and its metabolites as well as CYP2D6 activity measured by dextromethorphan to dextrorphan
Time Frame
Through study completion, an average of 2 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male and female (approximately 1:1) volunteers between the age of 18 and 55 years old and within 32% of your ideal body weight. Judged healthy without any significant medical condition as determined by and decided from a pre-enrollment screening session that include medical history, laboratory tests such as blood and urine tests, and an electrical tracing of the heart beat (electrocardiogram, EKG). Individuals who agree to refrain from taking any prescriptions medications, over-the-counter medications, and herbal, dietary, and alternative supplements that may interact with the metabolism of those study drugs at least 2 weeks prior to the start of the study and until study completion. Nonsmoker or individuals willing to refrain from smoking or use of tobacco or marijuana for at least two weeks prior to and until the completion of the study (the entire study lasts for approximately 32 days). Willing to commit the time requested for this study Exclusion Criteria: Subjects will be excluded from the study if they: Are underweight (weigh less than 52 kg or 114 lb) or overweight [body mass index (BMI) greater than 32]. Have laboratory results that do not fall in a healthy range (e.g., blood hemoglobin less than 12.0 mg/dl). Have baseline EKG readings that are abnormal that could place the patient at the higher risk as decided by the study medical doctor (MD) Have history of intolerance, allergic reactions (e.g. rash) or other forms of hypersensitivities to any of the study medications (dextromethorphan and bupropion). Have current alcohol (more than 4 alcoholic drinks per day on a regular basis) or drug abuse. Have history or current gastrointestinal (digestive) disorders such as persistent diarrhea or malabsorption that would interfere with the absorption of orally administered drugs Have history or current seizures, hypertension and heart disease or any other cardiovascular disorders Have history or current psychiatric (mental or brain) disorders (e.g., feeling sad or unhappy, loss of interest in normal activities, worried) such as depression, anxiety, or suicidality or suicide attempts. Have significantly compromised liver and/or kidney functions. Have participated in a research study involving intensive blood sampling or have donated blood within the past two months Are unable or unwilling to stop taking other substances that may interfere with the metabolism of the study drugs (bupropion and dextromethorphan) two weeks prior to and during the entire study period, including prescription medications, over-the-counter medications, herbal or dietary supplements, and alternative medicines. Are employees or students under supervision of any of the study investigators. Cannot state a good understanding of this study including risks and requirements; are unable to follow the rules of this study. Cannot commit the time requested for this study.
Facility Information:
Facility Name
Indiana Clinical Research Center (ICRC)
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

We'll reach out to this number within 24 hrs